CAGR of 63% forecast for NASH market across the US and five EU countries, says analyst

18 December 2018

In anticipation of new drug approvals in a therapy sector that has no current treatments available but many in the research pipeline, the market for non-alcoholic steatohepatitis (NASH) is expected to see rapid growth.

The market for NASH is set to expand at a compound annual growth rate (CAGR) of 63% across the USA and the five major European markets (5EU; France, Germany, Italy, Spain and the UK) to reach $18.3 billion by 2026, according to data and analytics company GlobalData. An earlier report from the company put NASH product sales at $138.4 million in 2016.

GlobalData says that both the attractive market potential and the significant unmet needs for NASH, which has no FDA-approved products, stimulated mergers and acquisitions and strategic alliance deal activity between 2014 and 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK